AMDL, Inc. Files Patent for Novel Cancer Diagnostic System
TUSTIN, Calif., July 24 /PRNewswire/ -- AMDL, Inc. (OTC Bulletin Board: AMDD) today announced that it has filed for patent protection for a novel immunoassay,
Oncochek(TM) which AMDL scientists have developed for the detection of a number of cancers. The assay uses a monoclonal antibody to an octopeptide, and a
polyclonal antibody to measure the level of fibrinogen degradation products, (FDP), in the serum of a cancer patient. FDP level in cancer patients is elevated due to an
increased secretion of protein degrading enzymes by the tumor cells.
Serum from incompletely clotted blood does not appear to cause any problems with the assay. As a result it is not as sensitive to the manner in which the serum sample
is collected, and is less prone to false positive readings. Preliminary findings indicate that FDP levels in serum of cancer patients are elevated. Such findings are
consistent with the widely accepted finding that growing tumors have an increased rate of protease release.
AMDL, Inc. is a biomedical company applying immunochemical technology to develop novel diagnostic tests for use in the diagnosis of cancer and other diseases.
NOTE: Certain statements in this announcement that relate to AMDL, Inc.'s plans, objectives or future performance may be deemed forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations. Actual strategies and results in
future periods may differ materially from those currently expected because of various risks and uncertainties. Additional discussion of factors affecting AMDL, Inc.'s
business and prospects is contained in its periodic filings with the Securities and Exchange Commission. |
